Answers are grounded in this paper and cite their sources.
Although the survival free of disabling stroke or reoperation to replace/remove a malfunctioning device at 2 years with the HM 3 left ventricular assist device did not differ by race, Black HeartMate 3 patients experienced a higher morbidity burden and smaller gains in functional capacity and quality of life when compared with White patients. These findings require efforts designed to better understand and overcome these gaps through systematic identification and tackling of putative factors. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02224755 and NCT02892955.
No takes yet. Share an insight, caveat, or question.
Sheikh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: